- STAT+: Biogen Alzheimer’s drug slowed decline at rates on par with approved therapies, study showsAn experimental Alzheimer's drug from Biogen, one with a novel approach, slowed decline at comparable rates as approved drugs in a mid-stage study.STAT · 12d ago↗ source
- Draig nets $65M to advance depression drug aimed at rebuilding synapsesDraig Therapeutics has secured $65 million in an oversubscribed Series B raise to advance a pipeline of neuropsychiatry drugs, including its lead depression program designed to modulate the AMPA re…Endpoints · 12d ago↗ source
- Genetic medicine startup Lyora launches with programs from Editas, BiogenLyora Therapeutics will try to revive several early-stage genetic eye disease programs previously held by Editas Medicine and Biogen. The biotech was co-founded by Luk Vandenberghe and Eric Pie…